Quality of survival: a new concept framework to assess the quality of prolonged life in cancer

Figures & data

Table 1. Overview of landscaping research.

Search category	Search strategy
Review of literature	Electronic bibliographic database (MEDLINE) searched for published literature relevant to QoS Search terms include cancer survivorship, cancer survivor, cancer trajectory, survivor versus survivorship, survivor identity, value of hope, economic impact of survivorship, survivorship programs, QoL and survivorship, lung, melanoma, prostate, breast, long-term cancer survivors, symptom burden, patient engagement, education, self-management, empowerment, association between patient engagement and QoL, impact of survivorship on physician
Clinical, public health, and academic associations	The associations of interest were identified through using the following search terms in an internet search engine: cancer survivorship, cancer survivor, survivor versus survivorship, cancer trajectory survivorship, survivorship programs, lung, melanoma, prostate, breast, patient engagement, education, self-management, empowerment PCORI website (http://www.pcori.org/; search terms: QoS, survivorship, cancer)
Patient/caregiver blogs, forums, and surveys	Search terms include patient, blogs, survey, forum, cancer, lung cancer, melanoma
Policy, HTA, and regulatory decision-maker resources	Regulatory guidance (EMA and FDA) in oncology, melanoma, and lung cancer (search terms: oncology, lung cancer, NSCLC, melanoma, PRO, QoL) HTA guidance (NSCLC HTA review provided by BMS)
Clinical development and research and development	Review of ongoing/recently completed phase II–IV trials (Clinicatrials.gov review; search terms: NSCLC and melanoma, 2012–current) Review of competitor product websites News in lung and melanoma relating to novel immuno-oncology therapies (Google ‘news’ search, 2012–current; search terms: NSCLC or melanoma and immuno-oncology)

BMS, Bristol-Myers Squibb; EMA, European Medicines Agency; FDA, US Food and Drug Administration; HTA, health technology assessment; NSCLC, non-small cell lung cancer; PRO, patient-reported outcome; QoL, quality of life; QoS, quality of survival.

Figure 1. Preliminary QoS concept map developed based on literature research.

Figure 2. (a) Patient views on characteristics of ‘good day’ with cancer. (b) Patient views on characteristics of ‘bad day’ with cancer.

Figure 3. (a) Impacts throughout the disease/treatment continuum on metastatic NSCLC patients (n = 20); (b) Impacts throughout the disease/treatment continuum on metastatic melanoma patients (n = 15).

Figure 4. (a) Clinician-endorsed QoS concept map. (b) QoS concept map dimensions along the care continuum.